Mytos
mytos.bioScaling Regenerative Medicine to Millions of Patients.
Health & Wellnessregenerative-medicinecell-therapybiotechautomationcdmomanufacturinggene-therapy
About
Mytos is an automated contract development and manufacturing organization (CDMO) for regenerative medicine, powered by its proprietary iDEM technology. The iDEM platform automates all unit operations in cell culture using standard 2D T flask formats, reducing labor per batch by up to 10x and cutting batch costs by up to 50% compared to manual CDMOs. Mytos offers end-to-end manufacturing services—from process development to regulatory support—without suite fees or device purchase requirements.
Problem
Scaling regenerative medicine manufacturing is slow, expensive, and labor-intensive, creating barriers for companies moving from early-stage to commercialization.
For
Biotech and cell therapy companies developing regenerative medicine products for clinical and commercial scale
How it works
Mytos provides automated CDMO services using its iDEM technology, which ports existing manual cell culture protocols into closed automation without altering the biology, enabling scalable and consistent GMP production.
Business model
unknown
Status
launched
Company
Mytos